KFP
ALXN

KB Financial Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

KB Financial Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14
Closed -$3K – 608
2021
Q2 		$3K Sell
14
-1,232
-99% -$211K ﹤0.01% 537
2021
Q1 		$191K Buy
+1,246
New +$193K 0.08% 151

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

KB Financial Partners's ALXN Position: Q3 2021 in Review

KB Financial Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 14 shares — an estimated $3K sold.

KB Financial Partners first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $191K in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • KB Financial Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • KB Financial Partners sold 14 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3K.
  • KB Financial Partners first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • KB Financial Partners's Alexion Pharmaceuticals position peaked at $191K in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on KB Financial Partners's 13F filing for Q3 2021, filed 16 Nov 2021.